ZFP36 and metabolic dysfunction-associated steatotic liver disease: This CO-dependent TTP activation reduces PAI-1 levels in SGs, potentially alleviating age-related NAFLD and highlighting TTP as a novel therapeutic target in age-associated liver disease [123].